Back to Search
Start Over
Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.
- Source :
-
Future oncology (London, England) [Future Oncol] 2024 Sep 19, pp. 1-20. Date of Electronic Publication: 2024 Sep 19. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Acute myeloid leukemia (AML) is caused by a defective precursor leading to malignant clonal expansion, often with FMS-like tyrosine kinase-3 receptor (FLT3) mutations, particularly internal tandem duplication (ITD), which has a poor prognosis. Quizartinib, a second-generation FLT3 inhibitor, has FDA approval for relapsed/refractory AML with FLT3/ITD mutation. It has shown promise in clinical studies since 2013 due to its excellent oral absorption and potent activity on FLT3. This review explores Quizartinib's mechanism of action, efficacy in monotherapy or combination with chemotherapy, drug interactions, adverse events, resistance mechanisms and future research directions.
Details
- Language :
- English
- ISSN :
- 1744-8301
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 39297694
- Full Text :
- https://doi.org/10.1080/14796694.2024.2399425